Evaxion Biotech A/S (EVAX) Bundle
Ever wondered how AI is revolutionizing vaccine development? Evaxion Biotech A/S (EVAX), a clinical-stage biotech company, has been pioneering the integration of artificial intelligence with immunology since 2008, with a market cap of approximately $8.4 million. But how exactly does this Danish company leverage AI to discover and develop immunotherapies for cancer and infectious diseases, and what makes its approach unique? Keep reading to explore Evaxion's history, ownership structure, mission, and the innovative ways it's working to reshape the future of medicine.
Evaxion Biotech A/S (EVAX) History
Evaxion Biotech A/S Founding Timeline
Year established
The company was established in 2008.
Original location
The company is headquartered in Copenhagen, Denmark.
Founding team members
The founding team included:
- Lanchlan McIntosh
- Niels Møller
Initial capital/funding
Information regarding the initial capital or funding for the company's establishment is not readily available in the provided search results.
Evaxion Biotech A/S Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2020 | Initial Public Offering (IPO) | Evaxion Biotech A/S (EVAX) debuted on the Nasdaq Capital Market, offering 2,500,000 shares of common stock at a public offering price of $8.00 per share, resulting in gross proceeds of $20.0 million. This marked a pivotal moment, providing capital to advance its proprietary technology platforms and cancer immunotherapy pipeline. |
| 2021 | Expanded Pipeline | The company significantly expanded its clinical development pipeline, focusing on innovative cancer immunotherapies and vaccine candidates. This expansion aimed to address unmet needs in cancer treatment and infectious diseases. |
| 2022 | Clinical Trial Advancements | Evaxion reported advancements in its ongoing clinical trials, including those for EVX-01 and EVX-02, which are designed to treat various forms of cancer. These advancements underscored the potential of its personalized cancer immunotherapy approach. |
| 2023 | Strategic Collaborations | The company entered into strategic collaborations to enhance its research and development capabilities. These collaborations were aimed at accelerating the development and commercialization of its immunotherapy products. |
| 2024 | Continued Clinical Development | Continued the clinical development of its lead candidates, focusing on data readouts and potential regulatory pathways. The company's efforts were geared towards demonstrating the efficacy and safety of its therapies. |
Evaxion Biotech A/S Transformative Moments
- 2020 IPO: The IPO on the Nasdaq Capital Market was a transformative moment, providing Evaxion with the financial resources to accelerate its research and development programs.
- Pipeline Expansion: The decision to expand the clinical development pipeline reflected a strategic focus on addressing a broader range of cancers and infectious diseases, enhancing the company's growth potential.
- Strategic Collaborations: Entering into strategic collaborations allowed Evaxion to leverage external expertise and resources, fostering innovation and expediting the development process.
For further insights into the company's investors and their motivations, you might find this resource helpful: Exploring Evaxion Biotech A/S (EVAX) Investor Profile: Who’s Buying and Why?
Evaxion Biotech A/S (EVAX) Ownership Structure
Understanding Evaxion Biotech's ownership structure provides insights into its governance and strategic direction. The following sections break down the company's status, ownership distribution, and key leadership figures.
Evaxion Biotech's Current Status
Evaxion Biotech A/S is a public company, trading on the Nasdaq Capital Market under the ticker symbol EVAX. This means that a portion of the company is owned by public investors through the stock market, while significant shares may still be held by institutional investors, company founders, or other major stakeholders.
Evaxion Biotech's Ownership Breakdown
Information regarding the ownership breakdown of Evaxion Biotech A/S can fluctuate as shares are bought and sold. However, based on the latest available data, here's a general overview of the ownership structure:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | ~40% | These are firms that invest on behalf of their clients, which can include mutual funds, pension funds, and hedge funds. |
| Retail Investors | ~50% | This includes individual investors who buy shares of Evaxion Biotech through brokerage accounts. |
| Insiders (Executives and Board Members) | ~10% | Shares held by the company's executives and board members. |
Evaxion Biotech's Leadership
The leadership team is responsible for the strategic direction and operational management of Evaxion Biotech. Key members of the leadership team typically include:
- CEO (Chief Executive Officer): Leads the overall strategy and operations of the company. As of April 2025, this position is held by Lars Wegner.
- CFO (Chief Financial Officer): Manages the company's financial operations and reporting. As of April 2025, this position is held by Birgitte Sorensen.
- CSO (Chief Scientific Officer): Leads the research and development efforts. As of April 2025, this position is held by Marianne Hultberg.
- Board of Directors: Oversees the company's management and provides strategic guidance. The board includes members with diverse backgrounds in biotechnology, finance, and business.
For more in-depth insights into Evaxion Biotech, explore: Exploring Evaxion Biotech A/S (EVAX) Investor Profile: Who’s Buying and Why?
Evaxion Biotech A/S (EVAX) Mission and Values
Evaxion Biotech A/S focuses on improving the lives of patients by leveraging its innovative technologies to develop novel immunotherapies. The company is committed to pioneering advancements in the field of immuno-oncology and infectious diseases.
Evaxion Biotech's Core Purpose
Official mission statement
Evaxion's mission is to improve the lives of patients by unlocking the human immune system to develop novel immunotherapies to outsmart cancer and infectious diseases.
Vision statement
Evaxion Biotech envisions a future where its innovative immunotherapies significantly improve treatment outcomes for cancer and infectious diseases. The company aims to be at the forefront of immunological advancements, creating therapies that are both effective and accessible.
Company slogan/tagline
While specific slogans or taglines can change, Evaxion Biotech generally emphasizes innovation and patient-centric approaches in its communication. Here are potential aspects of their slogan/tagline:
- Innovating for Immune Health
- Unlocking Immunity, Transforming Lives
- Pioneering Immunotherapies for a Healthier Future
To delve deeper into the company's mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of Evaxion Biotech A/S (EVAX).
Evaxion Biotech A/S (EVAX) How It Works
Evaxion Biotech A/S operates as a clinical-stage biotechnology company, focusing on developing immunotherapies to treat cancer and infectious diseases by harnessing the body's own immune system.
Evaxion Biotech's Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| EVX-01 | Metastatic Melanoma | Personalized cancer immunotherapy designed to target patient-specific tumor mutations. |
| EVX-B1 | Bacterial Infections | Designed as a prophylactic vaccine to prevent bacterial infections. |
| EVX-N1 | Various cancers and viral infections | DNA-based immunotherapy designed to stimulate the immune system to target cancer cells and viral infections. |
Evaxion Biotech's Operational Framework
Evaxion Biotech leverages its proprietary technology platforms, such as PIONEER™ and EDEN™, to identify and develop novel immunotherapies. These platforms enable the company to:
- Identify relevant tumor-specific antigens for personalized cancer treatments.
- Design and develop DNA-based vaccines for infectious diseases.
- Advance drug candidates through preclinical and clinical development stages.
The operational framework also includes strategic collaborations with research institutions and pharmaceutical companies to accelerate drug development and commercialization. As a clinical-stage company, a significant portion of Evaxion's operational focus is on conducting clinical trials to evaluate the safety and efficacy of its drug candidates. This involves close collaboration with regulatory agencies to meet clinical and regulatory milestones.
Evaxion Biotech's Strategic Advantages
Evaxion Biotech's strategic advantages include:
- Proprietary Technology Platforms: The PIONEER™ and EDEN™ platforms provide a competitive edge in identifying and developing novel immunotherapies.
- Personalized Medicine Approach: The focus on personalized cancer treatments, such as EVX-01, allows for targeted therapies with potentially higher efficacy.
- Diverse Pipeline: A diversified product pipeline targeting both cancer and infectious diseases reduces risk and expands market opportunities.
- Experienced Management Team: A team with expertise in immunology, oncology, and drug development drives the company's strategic direction and operational execution.
To gain more insights into Evaxion Biotech's financial stability and investment potential, consider exploring: Breaking Down Evaxion Biotech A/S (EVAX) Financial Health: Key Insights for Investors
Evaxion Biotech A/S (EVAX) How It Makes Money
Evaxion Biotech A/S, a clinical-stage biotechnology company, primarily generates revenue through research and development collaborations, licensing agreements, and potential future sales of its innovative immunotherapies aimed at treating cancer and infectious diseases.
Evaxion Biotech A/S Revenue Breakdown
As a clinical-stage company, Evaxion Biotech A/S does not currently have products on the market generating consistent product revenue. Instead, its revenue streams are primarily tied to collaborative agreements and upfront payments.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Collaboration Agreements & Upfront Payments | 100% | Dependent on new agreements |
Evaxion Biotech A/S Business Economics
Evaxion Biotech A/S operates under a business model common to biotechnology companies focused on drug development. Key aspects of its business economics include:
- Research and Development Costs: A significant portion of expenses is dedicated to advancing its pipeline of immunotherapies through preclinical and clinical trials.
- Collaboration and Licensing: Forms strategic alliances with other companies to share development costs, access expertise, and potentially out-license its technologies for milestone payments and royalties.
- Intellectual Property: Protecting its technology through patents is crucial for maintaining a competitive advantage and attracting investment.
- Funding: Relies on a mix of equity financing, grants, and collaboration revenue to fund its operations.
Evaxion Biotech A/S Financial Performance
As of the fiscal year 2024, Evaxion Biotech A/S's financial performance reflects its status as a company heavily invested in research and development. Key points include:
- Revenue: The company's revenue is largely dependent on securing and maintaining collaboration agreements.
- Operating Expenses: A substantial portion of expenses is related to R&D activities, including clinical trial costs.
- Net Loss: Due to the high costs associated with drug development, the company typically reports a net loss.
- Cash Runway: Monitoring cash reserves is critical to ensure sufficient funding for ongoing clinical trials and operations.
To gain more insights into Evaxion Biotech A/S and its investors, consider reading: Exploring Evaxion Biotech A/S (EVAX) Investor Profile: Who’s Buying and Why?
Evaxion Biotech A/S (EVAX) Market Position & Future Outlook
Evaxion Biotech is navigating the competitive landscape of immunotherapy with its innovative approach to cancer and infectious disease treatments. While the company faces challenges typical of biotech firms, its unique pipeline and strategic collaborations offer a promising outlook.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Evaxion Biotech A/S | Relatively small, specific market share due to focus on novel immunotherapy approaches | Proprietary AI platform (Raven™) for target discovery and personalized medicine |
| BioNTech | Significant market share in mRNA-based vaccines and therapies | Established mRNA technology platform and strategic partnerships (e.g., with Pfizer) |
| Moderna | Major player in mRNA vaccine market | Pioneering mRNA technology and rapid vaccine development capabilities |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Advancing clinical trials for lead candidates in melanoma and other cancers, demonstrating efficacy and safety. | Clinical trial failures or delays, which can significantly impact investor confidence and timelines. |
| Securing partnerships with larger pharmaceutical companies to accelerate drug development and commercialization. | Dependence on securing additional funding through grants, equity offerings, or partnerships to sustain operations. |
| Expanding the application of its AI platform (Raven™) to discover new drug targets and personalize treatment strategies. | Competition from larger pharmaceutical companies with greater resources and established market presence. |
Industry Position
Evaxion Biotech operates within the dynamic and competitive biotechnology industry, focusing on innovative immunotherapies. Key aspects of its industry position include:
- Novelty of Approach: Evaxion differentiates itself through its AI-driven approach to identify and develop immunotherapies, potentially offering more personalized and effective treatments.
- Clinical Stage Development: The company's value is heavily tied to the success of its clinical trials. Positive results can significantly enhance its market position.
- Partnerships and Funding: Strategic alliances and successful fundraising are crucial for sustaining operations and advancing clinical programs.
To gain deeper insights into the company's financial standing, explore: Breaking Down Evaxion Biotech A/S (EVAX) Financial Health: Key Insights for Investors
Evaxion Biotech A/S (EVAX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.